Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Andrew McGrath und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48104, United States. Hauptthemen laut MEDLINE: Transcription Factors, Proteolysis, Cell Cycle Proteins, Amines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NIGMS NIH HHS, Alfred P. Sloan Foundation, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Protein degradation using proteolysis targeting chimeras (PROTACs) represents a promising therapeutic strategy. PROTACs are heterobifunctional molecules that consist of a target-binding moiety and an E3 ligase binding moiety, connected by a linker. These fragments are frequently united via amide bonds. While straightforward to synthesize, amides may impart suboptimal drug properties to the overall molecule. From a systems level perspective, we envisioned that the potency of PROTACs could be modulated through selection of reaction conditions─wherein different catalysts produce distinct linkers from the same two building blocks. We present a suite of BRD4 PROTAC degraders prepared via four new amine-acid coupling reactions alongside the classic amide coupling. Our findings reveal that variations in reaction conditions affect the physicochemical properties of PROTACs, resulting in a spectrum of properties. Notably, several new PROTACs demonstrated enhanced BRD4 degradation efficacy compared to those employing amide linkers, emphasizing the potential of systems chemistry as a therapeutic optimization strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48104, United States.
- Therapeutics Discovery, Janssen Research & Development, LLC, La Jolla, California 92121, United States.
- Therapeutics Discovery, Janssen Research & Development, LLC, Spring House, Pennsylvania 19477, United States.
ORCID-Profile: Andrew McGrath, Christine F Gelin, Tim Cernak
Förderung
- NIGMS NIH HHS
- Alfred P. Sloan Foundation
- National Institute of General Medical Sciences
- Johnson & Johnson Innovative Medicine
Zitieren
APA
McGrath, A., Huang, H., Brazeau, J. F., Zhang, Z., Audu, C. O., Vellore, N. A., Zhu, L., Shi, Z., Venable, J. D., Gelin, C. F., & Cernak, T. (2025). Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02047
Vancouver
McGrath A, Huang H, Brazeau JF, Zhang Z, Audu CO, Vellore NA, et al. Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02047
BibTeX
@article{McGrath2025,
author = {McGrath, Andrew and Huang, Haiyan and Brazeau, Jean-Francois and Zhang, Zirong and Audu, Christopher O and Vellore, Nadeem A and Zhu, Lu and Shi, Zhicai and Venable, Jennifer D and Gelin, Christine F and Cernak, Tim},
title = {Modulating the Potency of BRD4 PROTACs at the Systems Level with Amine-Acid Coupling Reactions},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02047}
}
EUVIMED